United States Patent 4,616,006: Triphasic 21-Day Oral Contraceptive Unit With Fixed Estrogen Across Phases
US drug patent US 4,616,006 claims a triphasic, 21-tablet (or dosage-unit) oral contraceptive regimen with sequential daily dosing over 21 days. The central claim logic is a fixed daily estrogen across all three phases (same 17α-ethinylestradiol-equivalent activity in phase 1, 2, and 3) paired with stepwise escalation of progestogenic dose (as norethindrone-equivalents) across the three phases.
What is the claimed product structure and dosing logic?
Claim 1: triphasic 21-unit oral contraceptive with identical estrogen across phases
Claim 1 defines a triphasic oral contraceptive unit with 21 separate dosage units, adapted for successive daily oral administration, in which:
Claim 10: triphasic unit with variable phase lengths
Claim 10 expands the numerical structure while preserving the defining estrogen condition:
- Total unit is still triphasic oral contraceptive unit
- Still described for successive daily oral administration
- Phase length constraints are broadened:
- Phase 1: 5 to 8 dosage units
- Phase 2: 7 to 11 dosage units
- Phase 3: 3 to 7 dosage units
- Optional: 6 to 8 dosage units free of estrogen and progestogen
- The same defining narrowing condition persists:
- “provided that the estrogen daily dosage is the same in all three phases.”
Key difference between claim 1 and claim 10: claim 1 fixes 7 units per phase; claim 10 permits phase-length flexibility while keeping estrogen daily dosage constant across phases.
What are the dependent claims that narrow the regimen?
Form factor
- Claim 2: dosage units are tablets.
Estrogen selection
- Claim 3: estrogen selected from:
- 17α-ethinylestradiol, estrone, estradiol, estriol.
- Claim 4: estrogen is 17α-ethinylestradiol.
Progestogen selection
- Claim 5: progestogen selected from:
- D-norgestrel, norethindrone, progesterone, D-17β-acetoxy-13β-ethyl-17α-ethinyl-gon-4-en-3-one oxime.
- Claim 6: progestogen is norethindrone.
- Claim 7: progestogen is D-17β-acetoxy-13β-ethyl-17α-ethinyl-gon-4-en-3-one oxime.
Concrete example dosing equivalents
Claim 8 and claim 9 provide explicit equivalent schedules that sit inside the broader ranges of claim 1.
How broad is the claimed “estrogen” and “progestogen” space?
Estrogen
Across all phases, estrogen activity must correspond to:
- 0.02–0.05 mg 17α-ethinylestradiol per day, and
- the same daily estrogen dosage in phases 1, 2, and 3.
Dependent claims then optionally narrow the estrogen identity:
- Could be any of four steroids (claim 3), or specifically 17α-ethinylestradiol (claim 4).
Progestogen
The progestogenic escalation is expressed as “norethindrone-equivalent” ranges in claim 1:
- Phase 1: 0.065–0.75 mg
- Phase 2: 0.25–1.0 mg
- Phase 3: 0.35–2.0 mg
Dependent claims then broaden progestogen identity options:
- norethindrone (claim 6) and other listed progestogens (claim 5), plus a specific alternative structure (claim 7).
Implication for scope: the patent is not limited to a single progestogen; it uses equivalency dosing language and allows multiple progestogens, as long as the progestogenic effect maps into the claimed dose-equivalent bands.
Where are the likely claim “pressure points” for infringement or design-around?
Pressure point 1: constant estrogen daily dose across all three phases
This is the cleanest technical discriminator in the claims:
- If the regimen changes estrogen daily dose across phases, it does not satisfy the “estrogen daily dosage is the same in all three phases” limitation in claim 1/10.
- This provides a direct design-around axis for triphasic products that vary estrogen rather than only progestogen.
Pressure point 2: progestogenic escalation pattern and phase ranges
Even with constant estrogen, infringement hinges on progestogen dose equivalence in each phase:
- Phase 1 must fall into 0.065–0.75 mg norethindrone-equivalent
- Phase 2 into 0.25–1.0 mg
- Phase 3 into 0.35–2.0 mg
and must do so in the context of the claimed phase structure (7/7/7 in claim 1; variable in claim 10).
Pressure point 3: phase length and off-hormone options
- Claim 1 uses 7/7/7 for phases.
- Claim 10 allows 5–8 / 7–11 / 3–7 while still requiring the same estrogen each phase.
- The language about optional “dosage units free of estrogen and progestogen” creates ambiguity in how those units are counted in practice, but it gives the patentee an argument that regimens with off-hormone tablets can still fit the claimed triphasic sequence.
Pressure point 4: dosage-unit count and daily regimen format
The claims are tied to an oral contraceptive unit with separate dosage units for successive daily oral administration:
- A competitor using a different dosing cadence (not “successive daily oral administration” in the same unit structure) may avoid literal structure, though functional equivalence arguments would still arise depending on claim construction.
What does the claim set say about “what is not claimed”?
Based on the text of the claims provided, key exclusions are structural:
- The claims are triphasic; they do not read on monophasic regimens.
- The defining estrogen limitation requires estrogen daily dosage equal in all three phases.
- The dosing logic is tied to estrogen + progestogen combinations for the phase units, with optional estrogen/progestogen-free tablets depending on how the “optionally containing” language is interpreted.
Patent landscape: how US 4,616,006 is positioned relative to typical contraceptive product IP themes
Landscape role of this patent
US 4,616,006 is typical of legacy contraceptive IP strategies in that it:
- claims a regimen architecture (triphasic daily schedule over a defined number of dosage units), and
- claims numeric dose-equivalency ranges for estrogen and progestogen across phases, and
- adds dependent coverage for specific estrogen identity, specific progestogen identity, and example equivalent schedules.
Most relevant “surrounding” competitor design choices
In practice, other triphasic contraceptive products tend to vary one or more of the following:
- Estrogen dose across phases (vary vs constant)
- Progestogen type (norethindrone vs norgestimate vs others)
- Progestogen step-up magnitude (dose band overlap or not)
- Tablet counts per phase and whether placebo/off-hormone tablets are included
This patent most directly claims the “constant estrogen, step-up progestogen” pattern.
How this affects freedom-to-operate mapping
When mapping the landscape for product entry or generic development, the key technical mapping tasks are:
- Check whether the candidate regimen meets:
- triphasic structure
- same estrogen daily dose in each phase
- progestogen-equivalent doses that fall within the defined ranges per phase
- Then check whether the candidate also matches narrower dependent claims:
- tablets form (claim 2)
- estrogen identity (claim 3/4)
- progestogen identity (claim 5/6/7)
If the candidate breaks the estrogen constancy limitation, the literal claim path weakens sharply because it is the explicit defining condition in claim 1 and claim 10.
Claim chart style mapping (high-signal)
Below is a compact “must-have” mapping for claim 1. Any candidate that fails one must-have likely avoids claim 1 literal coverage.
| Claim 1 element |
What the patent requires |
Product design implication |
| Triphasic oral contraceptive unit |
21 separate dosage units for successive daily oral administration |
Must be a regimen with 3 phases across daily tablets |
| Phase 1 composition |
Estrogen + progestogen with 17α-ethinylestradiol-equivalent 0.02–0.05 mg and norethindrone-equivalent 0.065–0.75 mg |
Phase 1 progestogen step-up begins here |
| Phase 2 composition |
Same estrogen equivalent range; progestogen 0.25–1.0 mg |
Progestogen increases vs phase 1 |
| Phase 3 composition |
Same estrogen equivalent range; progestogen 0.35–2.0 mg |
Progestogen reaches highest level in phase 3 |
| Defining estrogen constraint |
Estrogen daily dosage is the same in all three phases |
Direct design-around lever: vary estrogen by phase |
| Optional off-hormone units |
Optionally includes units free of estrogen/progestogen |
Candidate must be evaluated for whether it still meets triphasic phase dose structure |
Key Takeaways
- US 4,616,006 claims a triphasic 21-day oral contraceptive regimen built on constant estrogen dose across phases and escalating progestogen dose by phase.
- Claim 1 defines numeric dose-equivalency bands for estrogen and progestogen and locks estrogen to be the same daily amount in all three phases.
- Claim 10 broadens phase length counts but keeps the same defining estrogen constancy limitation.
- Dependent claims add coverage for tablets and specific estrogen/progestogen selections and include explicit example equivalent schedules (claims 8 and 9).
- The most direct scope discriminator for competitors and generic developers is whether their triphasic regimen changes estrogen daily dose across phases versus holding it constant.
FAQs
1) Does US 4,616,006 require 17α-ethinylestradiol as the estrogen?
No. Claim 1 covers estrogen by activity equivalence to 17α-ethinylestradiol (0.02–0.05 mg equivalent), and dependent claim 3 lists alternative estrogens; dependent claim 4 narrows to 17α-ethinylestradiol.
2) What is the single clearest design-around lever in the claims?
The requirement that “the estrogen daily dosage is the same in all three phases.” A regimen that varies estrogen by phase is outside this defining limitation in claim 1 and claim 10.
3) Is the patent limited to norethindrone as the progestogen?
No. Claim 1 uses norethindrone-equivalent progestogenic activity ranges, while dependent claim 5 lists multiple progestogens and dependent claims 6 and 7 narrow to specific progestogens.
4) Do the claims require exactly 7 tablets per phase?
Not across the whole claim set. Claim 1 uses 7/7/7; claim 10 allows variable phase lengths (5–8 / 7–11 / 3–7), while maintaining the constant estrogen condition.
5) What do claims 8 and 9 add beyond the ranges?
They provide specific example schedules:
- Claim 8: 0.035 mg estrogen equivalent daily across phases with progestogen equivalents of 0.50 / 0.75 / 1.0 mg norethindrone across phases.
- Claim 9: 0.035 mg estrogen equivalent daily across phases with progestogen equivalents of 0.180 / 0.215 / 0.250 mg norgestimate across phases.
References
[1] US Patent 4,616,006. Claims 1-10 (triphasic oral contraceptive unit with estrogen and progestogen dose equivalence and constant estrogen across phases).
